{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:42:27Z","timestamp":1793108547378,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41375-026-03112-z","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:05:42Z","timestamp":1787054742000},"page":"2592-2596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modeling KRAS mutations in KMT2A::MLLT3 acute myeloid leukemia promotes leukemic progression and transcriptional rewiring"],"prefix":"10.1038","volume":"40","author":[{"given":"Nayeli","family":"Esparza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Defr\u00eane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Bresson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7065-7791","authenticated-orcid":false,"given":"Anne-C\u00e9cile","family":"Soufflet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Mar\u00eda","family":"Ju\u00e1rez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-4219","authenticated-orcid":false,"given":"Veronique","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6601-3096","authenticated-orcid":false,"given":"Alberto","family":"Hern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-5510","authenticated-orcid":false,"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9095-0066","authenticated-orcid":false,"given":"Vincent-Philippe","family":"Lavall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9360-3887","authenticated-orcid":false,"given":"Brian T.","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-3611","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Barab\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"3112_CR1","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Groger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988\u20131005.","journal-title":"Leukemia"},{"key":"3112_CR2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26731","volume":"97","author":"D Rivera","year":"2022","unstructured":"Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, et al. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022;97:1599\u2013606.","journal-title":"Am J Hematol"},{"key":"3112_CR3","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020;80:2969\u201374.","journal-title":"Cancer Res"},{"key":"3112_CR4","doi-asserted-by":"publisher","first-page":"26340","DOI":"10.1073\/pnas.2014732117","volume":"117","author":"M Bill","year":"2020","unstructured":"Bill M, Mrozek K, Kohlschmidt J, Eisfeld AK, Walker CJ, Nicolet D, et al. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A. Proc Natl Acad Sci USA. 2020;117:26340\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3112_CR5","doi-asserted-by":"crossref","unstructured":"Alawieh D, Cysique-Foinlan L, Willekens C, Renneville A. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives. Blood Cancer J. 2024;14:72.","DOI":"10.1038\/s41408-024-01054-2"},{"key":"3112_CR6","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-S\u00e1nchez A, Gonz\u00e1lez T, Sobas M, Str\u00e4ng E, Castellani G, Ab\u00e1igar M, et al. Rearrangements involving 11q23.3\/KMT2A in adult AML:mutational landscape and prognostic implications \u2013 a HARMONY study. Leukemia 2024;38:1929\u20131937 (2024).","DOI":"10.1038\/s41375-024-02333-4"},{"key":"3112_CR7","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/nbt1350","volume":"25","author":"F Ishikawa","year":"2007","unstructured":"Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315\u201321.","journal-title":"Nat Biotechnol"},{"key":"3112_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1139851","volume":"316","author":"F Barabe","year":"2007","unstructured":"Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science. 2007;316:600\u20134.","journal-title":"Science"},{"key":"3112_CR9","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1182\/blood-2005-02-0557","volume":"106","author":"D Reynaud","year":"2005","unstructured":"Reynaud D, Ravet E, Titeux M, Mazurier F, Renia L, Dubart-Kupperschmitt A, et al. SCL\/TAL1 expression level regulates human hematopoietic stem cell self-renewal and engraftment. Blood. 2005;106:2318\u201328.","journal-title":"Blood"},{"key":"3112_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.stem.2018.10.016","volume":"24","author":"SM Park","year":"2019","unstructured":"Park SM, Cho H, Thornton AM, Barlowe TS, Chou T, Chhangawala S, et al. IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. Cell Stem Cell. 2019;24:153\u201365 e7.","journal-title":"Cell Stem Cell"},{"key":"3112_CR11","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1172\/JCI66129","volume":"124","author":"Y Chen","year":"2014","unstructured":"Chen Y, Peng C, Abraham SA, Shan Y, Guo Z, Desouza N, et al. Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. J Clin Invest. 2014;124:3847\u201362.","journal-title":"J Clin Invest"},{"key":"3112_CR12","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1182\/blood-2009-09-243139","volume":"115","author":"M Kinder","year":"2010","unstructured":"Kinder M, Wei C, Shelat SG, Kundu M, Zhao L, Blair IA, et al. Hematopoietic stem cell function requires 12\/15-lipoxygenase-dependent fatty acid metabolism. Blood. 2010;115:5012\u201322.","journal-title":"Blood"},{"key":"3112_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12957-024-03449-8","volume":"22","author":"S Dang","year":"2024","unstructured":"Dang S, Zhang S, Zhao J, Li W. Efficacy and toxicity of KRAS(G12C) inhibitors in advanced solid tumors: a meta-analysis. World J Surg Oncol. 2024;22:182.","journal-title":"World J Surg Oncol"},{"key":"3112_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116771","volume":"277","author":"D Pandey","year":"2024","unstructured":"Pandey D, Chauhan SC, Kashyap VK, Roy KK. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers. Eur J Med Chem. 2024;277:116771.","journal-title":"Eur J Med Chem"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03112-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03112-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03112-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:59:00Z","timestamp":1793105940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03112-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3112"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03112-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LB: honoraria from AbbVie, Amgen, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Otsuka, Pfizer, Roche, Sanofi, and Servier; research funding from Bayer, Jazz Pharmaceuticals. All other authors declare no competing financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations.\n                      Cord Blood (CB)-cells\n                      - Human CB samples were obtained according to procedures approved by the ethics research committees of the Centre Hospitalier Universitaire (CHU) de Qu\u00e9bec-Universit\u00e9 Laval and H\u00f4tel-Dieu de L\u00e9vis.\n                      Mice -\n                      All animal experiments were carried out in accordance with the guidelines of the Universit\u00e9 Laval Animal Protection Committee (Quebec City, QC, Canada) All ethics and animal protocols are approved and covered by the SIRUL number 137262.\n                      Patients -\n                      The findings of this study were validated using the HARMONY Alliance AML database, selecting adult patients with\n                      KMT2A-\n                      r AML who had available next-generation sequencing (NGS) myeloid panel data, contributed by several European centers or cooperative groups. Patient data uploaded to the HARMONY Platform underwent a double brokerage pseudonymization procedure in compliance with the General Data Protection Regulation and data were harmonized and transformed using the Observational Medical Outcomes Partnership Common Data Model. This analysis was conducted in accordance with the Declaration of Helsinki and approved by the HARMONY AML working group. Prior written informed consent had been obtained from all patients at their respective HARMONY partner institutions.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}